TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab &

Status Completed

Clinical Trial Summary

Primary Objective:To evaluate the efficacy and safety of TIP (paclitaxel + ifosfamide + cisplatin) combined with nimotuzumab & triprilimab as neoadjuvant treatment in locally advanced penile cancer.

Clinical Trial Description

Penile cancer is a rare malignant tumor, which often occurs in the inner plate of prepuce and glans. Squamous cell carcinoma is the most common pathological type. Lymph node metastasis is a crucial factor that leads to poor prognosis of penile cancer. The 5-year OS of penile cancer patients without lymph node metastasis is 90%. Still, it goes down sharply in patients with inguinal lymph node metastasis and pelvic lymph node metastasis, which is 50% and 0%, respectively. Using neoadjuvant chemotherapy to treat patients with locally advanced penile cancer (T4, any N stage, or any T stage, N3) may improve their prognosis. TIP (Paclitaxel + Ifosfamide + Cisplatin) regimen is the first line neoadjuvant treatment recommended by NCCN guidelines. Epidermal growth factor receptor (EGFR) plays a vital role in the development of penile cancer. It's also an important therapeutic target for penile cancer. PD-1 is an immune checkpoint molecule on the surface of T cells. In recent years, immune-checkpoint inhibitors targeting PD-1 have shown good efficacy in a variety of tumors. Some phase II / III clinical trials have shown that PD-1 inhibitors can improve the prognosis of patients with lung squamous cell carcinoma, head and neck squamous cell carcinoma and cervical cancer. Previous studies have found that PD-L1 is highly expressed in 40% - 60% of penile cancer, suggesting that penile cancer patients may benefit from immunotherapy. The management of penile cancer with lymph node metastasis is difficult, especially for N2-3 stage. This phase II study aim to explore an effective combination therapy for locally advanced penile cancer. 29 patients need to be enrolled.TIP & nimotuzumab & triprilimab will be administered per 21-day until surgery, evidence of disease progression or onset of unacceptable toxicity. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04475016
Study type	Interventional
Source	Sun Yat-sen University
Contact
Status	Completed
Phase	Phase 2
Start date	August 12, 2020
Completion date	May 30, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03686332` - PEnile Cancer Radio- and Immunotherapy CLinical Exploration Study	Phase 2
Completed	`NCT05518201` - Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old	Phase 1
Recruiting	`NCT04708470` - A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers	Phase 1/Phase 2
Active, not recruiting	`NCT04357873` - Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations	Phase 2
Terminated	`NCT00058448` - S0224, Docetaxel in Treating Patients With Locally Advanced or Metastatic Penile Cancer (TERMINATED)	Phase 2
Recruiting	`NCT02817958` - Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis	Phase 2
Completed	`NCT02280811` - T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers	Phase 2
Recruiting	`NCT02994758` - Development of Diagnostics and Treatment of Urological Cancers	N/A
Completed	`NCT00019110` - Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer	Phase 1
Completed	`NCT04574427` - INtra-operative Evaluation of a Novel FLUorescENt C-mEt Tracer in Penile and Tongue
Recruiting	`NCT02012699` - Integrated Cancer Repository for Cancer Research
Recruiting	`NCT05946993` - Linking In With Advice and Supports for Men Impacted by Metastatic Cancer	N/A
Recruiting	`NCT04028479` - The Registry of Oncology Outcomes Associated With Testing and Treatment
Recruiting	`NCT05686226` - E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers	Phase 2
Completed	`NCT05376202` - Image Guided Penile Cancer Surgery	Phase 1
Recruiting	`NCT05264337` - Lymphedema After Urologic Surgery
Recruiting	`NCT03774901` - Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma	Phase 2
Completed	`NCT01209325` - Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males	Phase 2
Recruiting	`NCT05592639` - VideoEndoscopic Radical Inguinal Lymphadenectomy for Penile Cancer	N/A
Completed	`NCT00066391` - Irinotecan and Cisplatin in Treating Patients With Locally Advanced or Metastatic Penile Cancer	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms